Objective to study the binding function of recombinant human serum albumin (HSA) to small molecule drugs.
目的研究重组人血白蛋白与小分子药物的结合功能。
Biologics have a somewhat better success rate than small molecule drugs, but they remain far from a sure bet.
生物技术药物研发的成功率稍高于小分子药物，但它们距离稳赚不赔的目标仍相距甚远。
Conclusion The binding functions of recombinant and nature HSA to small molecule drugs were basically in agreement.
结论重组人血白蛋白与天然人血白蛋白小分子药物结合功能基本一致。
But a number of drug companies including Genentech and Novartis AG are looking at small molecule cancer drugs that can get inside cells and block VEGF.
包括基因泰克和诺华制药在内的一些制药公司正在研究可以进入细胞内部并阻断VEGF的小分子抗癌药物。
The compound apparently blocks OATP1A2, a transporter molecule in the gut, which carries some drugs from the small intestine into the blood.
这种化合物似乎阻碍了一种叫OATP1A2的消化道中的运输分子，正是这种分子把某些药物从小肠运输到血液中。
Pfizer's biggest focus is "small molecule" drugs, meaning traditional oral medicines made from synthetic chemicals.
辉瑞公司的最大的重点是“小分子”药物，这意味着传统的口服药物由人工合成的化学品。
Many chronic neurological diseases cannot be treated with small-molecule drugs or do not respond well to them in long-term therapy.
基因治疗为许多无法用小分子药物治疗或小分子药物长期疗效不佳的神经系统疾病提供了希望。
The blood-brain barrier excludes from the brain 100% of large-molecule therapeutic factor and more than 98% of small-molecule drugs.
血脑屏障的存在使得几乎所有的大分子治疗因子和超过98%的小分子药物难以到达脑组织发挥其治疗作用。
The blood-brain barrier excludes from the brain 100% of large-molecule therapeutic factor and more than 98% of small-molecule drugs.
血脑屏障的存在使得几乎所有的大分子治疗因子和超过98%的小分子药物难以到达脑组织发挥其治疗作用。
应用推荐